Background. Solid organ transplanted patients have a three-to fourfold higher lifetime risk of developing a cancer than the general population. However, the incidence of a second primary cancer in transplanted patients has never been studied, despite the fact that the presence of regular follow-ups and the increased survival of these patients make them a very attractive model. Methods. We investigated the incidence of a second primary cancer (SPC) in 7,636 patients who underwent a kidney, liver, lung or heart transplant between 1970 and 2004, and were followed-up for 51,819 person-years. Results. During the follow-up, 499 subjects developed a first cancer (annual incidence: 98.6ϫ10,000 PY), and 22 of them developed a SPC (annual incidence: 3.9ϫ10,000 PY). The annual incidence of a SPC in the transplanted patients who developed a first cancer was 107.8ϫ10,000 PY, giving a standardized incidence ratio of 1.1 (95% CI: 0.83-1.41).
T he increasing access to sophisticated tools for early detection of cancer and the improving therapeutic schemes have modified the natural history of several types of cancer, and have largely increased the population size of cancer survivors. These subjects are exposed to the possibility of recurrence, or to the development of a second primary cancer (SPC) (1) (2) (3) (4) ; this is a cancer that based on time of occurrence, histological type, and site could be defined as a new event, rather than a metastasis or a recurrence of the first neoplasm. The risk of developing a SPC could be related to the persistence of environmental risk factors associated with the first cancer, and this is particularly evident for tobacco-related cancers (5) (6) (7) (8) (9) (10) . Individual susceptibility to carcinogens as well as other genetic factors could be responsible for the development of a SPC (11) (12) (13) . Furthermore, cancer patient survivors undergo more frequent and accurate screening programs and diagnostic scrutiny than non cancer patients, thus increasing the possibility of a detection bias.
Solid organ transplanted patients have a three-to fourfold higher lifetime risk of developing a cancer than the general population, with several hundred fold higher risks for certain types of virus related cancers, such as Kaposi's sarcoma (KS) and posttransplant lymphoproliferative diseases (PTLD) (14 -16) . At the best of our knowledge, the incidence of a SPC in transplanted patients has never been studied, despite the fact that the presence of regular follow-ups and the increased survival of these patients make them a very attractive model.
The aim of the present study was to investigate the incidence of a SPC in a network of Italian cohorts of kidney, liver, lung, and heart transplanted patients.
MATERIALS AND METHODS
The study represents the combination of a cohort collected through the North Italian Transplant program (NITp), and a network of cohorts collected through the Spallanzani Institute.
The design of the NITp cohort has been described elsewhere (14 All patients have signed an informed consent, which included the possibility to be contacted for follow up information. Along with an annual, active follow-up for each transplanted subject, the centers were asked to register all newly diagnosed cancers, identified either during their programmed usual clinical follow-up, or through telephone contact of the patients or their family members. This strategy of active surveillance has been put in place in order to avoid underreporting of cases. Data were entered in an electronic data base furnished by our Institute, which included personal information (age at transplant, sex, blood group, anti-HLA antibodies), transplant's information (date, transplant center, donor data, HLA mismatch, cold ischemic time, length of follow-up) and cancer data (site, type, date of diagnosis). Patients who survived less than 10 days after transplant, patients with a pretransplant history of any cancer, and patients who developed cancer within 30 days from transplant were excluded from this study, according to the protocol applied at the time of the cohort's recruitment (16) . Both basal cell and squamous carcinomas of the skin were excluded from the data base because of possible underreporting; however, they were included if they appeared as a SPC, since underreporting of a second cancer in subjects who already suffered a first malignancy is an unlikely event. A secondary analysis was performed including skin squamous cell carcinoma in the calculation of the incidence of both first and second primary cancer.
A cancer diagnosed in a subject who already suffered a malignancy after transplant, but was located in a different site from the first cancer and was histologically defined by the physician in charge of the patient as a "nonmetastatic" cancer, was recorded in this study as a SPC.
Each patient included in the cohort was actively followed up from the date of transplant to the date of cancer development, or death, and from the date of cancer development to the date of SPC development or death or study end date, for a total of 51,819 person-years (PY). First and second cancer incidence rates were calculated as the observed number of cases divided by PY at risk in the whole cohort, and according to gender and type of transplant. Standardized Incidence Ratio was calculated as the ratio between the incidence of SPC in subjects who had a first cancer divided by the incidence of the first cancer. 95% Confidence Intervals (CI) were calculated assuming a Poisson distribution.
RESULTS
The whole cohort included 7,636 transplanted patients, 6,725 of which were kidney, 159 were liver, 702 were heart, and 50 were lung transplants. During the follow-up period, 499 subjects were diagnosed with cancer, for an overall annual incidence of 98.6ϫ10,000 PY (95% CI: 90.0 -107.2). Differences in cancer incidence rate were observed according to gender: the incidence was 105.2ϫ10,000 PY in males vs. 77.5ϫ10,000 PY in females. Among the 7,636 patients included in this analysis, 22 (0.3%) developed a SPC, with an overall annual incidence of 3.9ϫ10,000 PY (95% CI 2.2-5.6) ( Table 1) . When the analysis was restricted to transplanted patients who developed a first cancer, the incidence rate of a SPC was 107.8ϫ10,000 PY (95% CI 63.0 -152.6), yielding a SIRϭ1.1 (95% CI: 0.83-1.41). When squamous cell carcinoma of the skin was included in the analysis, the incidence of first cancer was 117.7 ϫ10,000 PY, while the incidence of SPC in transplanted patients who developed a first cancer was 107.5, yielding a SIR of 0.97.
The details on the first and second cancers in subjects who developed a SPC are reported in Table 2 . Among solid tumors, the most frequent combination was kidney followed by skin cancer (nϭ3), while among lymphoproliferative diseases, two cases of Non Hodgkin Lymphoma (NHL) were followed by KS and kidney cancer; 1 case of Hodgkin Lymphoma (HL) was followed by NHL. Among SPC sites, skin cancer was the most frequent (nϭ11), followed by liver, and kidney (2 cases each).
The time of occurrence of the first tumor ranged from 33 to 5,585 days (mean 1,943Ϯ1,648 days), while the time of occurrence of the SPC after the first cancer ranged from 0 to 3,591 days (mean 778Ϯ963 days).
DISCUSSION
We report for the first time the incidence rates of a SPC in a network of cohorts of transplanted patients. Previous work on SPC has focused on samples of cancer patients, in order to analyze the carcinogenic mechanisms behind the development of both the first and the second cancer. For example, smoking related SPC in subjects affected by smoking related cancers (1, (5) (6) (7) (8) (9) (10) , and SPC of the reproductive organs in subjects with reproductive related cancers have been described (3, 11) , as well as skin cancer following melanoma (4) . Among the 7,636 patients included in the present cohort, 0.3% of the subjects developed a SPC; when considering only the transplanted individuals who developed a first cancer (nϭ499) 4.0% of them were diagnosed with a SPC. This figure is comparable to what has been previously published, where the percentage of SPC ranges from 1 to 5% (1, 2, 5, 6, 17) . However, such previous studies were restricted to subjects with a specific type of first cancer, while the present study has a cohort design, thus allowing calculation of the overall incidence of a SPC. As far as the type of SPC is concerned, the small number of second primary cases does not allow detecting any specific pattern of occurrence. Although the inclusion of squamous skin cancer may be questionable because of the specific nature of this cancer, we have decided to include it in order to give a global picture of SPC incidence in this population. In order to reach a large enough population to study patterns of occurrence of SPC, pooled analyses of transplanted patient registries would be necessary. This effort would also allow the study of SPC in relation to type of solid organ transplant and type of therapeutic regimen. In fact, a limitation of our study is that the small number of second primaries, along with the fact that immunosuppressive protocols have changed in Italy during the large time frame in which the study was conducted, did not allow the analysis of the association between drug type and dosage and SPC incidence.
The incidence of cancer in transplanted patients is known to be higher than in the general population, due to immunosuppressive treatments and possible viral infections. In the cohort described here, the overall annual incidence of first cancer was 98.6ϫ10,000 PY, corresponding to an increased risk of nearly 2.3 fold compared to that in the general population of the same sex and age (www.registri-tumori.it/ incidenza/main.htm). This result is in agreement with previously published data (14 -16) . However, the incidence of SPC in the subjects who developed a first cancer was 107.8ϫ10,000 PY, suggesting an incidence comparable to the incidence of the first cancer in the same population (Standardized Incidence Ratioϭ1.1). This result suggests that transplanted subjects who developed a first cancer do not have a significantly higher risk of developing a second cancer compared to their baseline risk of developing the first cancer, at least in our sample.
In conclusion, our study does not indicate a significant increased risk of SPC in transplanted subjects who already suffered of a first malignancy. Therefore, the clinical indication deriving from this study is that regular screening procedures should be applied to transplanted patients who had cancer, while no special indication to more frequent screenings or screening of specific sites in patients who already suffered a first cancer is suggested by this study.
